Instead, pramlintide, as an amylin agonist with improved water solubility to reduce the amyloid propensity [7], was approved by the US Food and Drug Administration in April 2005 for bolus premeal administration adjunct to insulin therapy in patients with diabetes mellitus [8]. This evidence concerns the gene IAPP and diabetes mellitus.